AVEO to raise $61 million through personal placement AVEO Pharmaceuticals.


AVEO to raise $61 million through personal placement AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, commercializing and developing a cancer therapeutics, today announced the execution of a securities purchase contract with a select band of institutional and accredited investors providing for an exclusive placement, or PIPE funding. Upon the closing of the PIPE funding, AVEO will receive gross proceeds of around $61 million resulting from the sale of 4.5 million shares of common stock at a price of $13.50 per share, which represents an approximate 7 percent discount to the closing cost on October 28, 2010.Multispecialty Medical Groups and Other Organized Systems of Treatment Make the Strongest Foundation for ACOs 2.ACOs SHOULD BE Physician-Led 3.ACOs Must Be Willing to Be Held Accountable for Clinical Results and Cost Efficiencies in the grouped communities Served 4.ACO Incentives Must Be Aligned to Foster Voluntary Participation 5.ACOs WILL NEED TO HAVE a Primary Care Core 6.ACOs OUGHT TO BE Learning Organizations That Gather and Use Data to boost the Performance and Safety of Individual Care Related StoriesReducing hospital readmissions through Transitional Care: an interview with Rani KhetarpalGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsCancer diagnosis improvements in England: an interview with Lucy Elliss-BrookesFor full text message of the principles, go to the AMGA ACO Source Center at As part of its continuing attempts to support the development of ACOs, the association also proceeds to host a series of meetings in 2010 2010 that gather the leaders of health care delivery systems to teach medical group leaders on how best to develop, operate, and maintain high-performing ACOs.